Take-home’ message for the clinician
Lung cancer continues to be the leading cause of cancer deaths. The
molecular landscape of lung canceris rapidly evolving leading to a
paradigm shift in the management ofadvanced non-small cell lung cancer.
The new therapeutic regimens are primarily designed to use target
therapies, mainly tyrosine kinase inhibitorsin patients with targeted
mutations and immunotherapies (with or without chemotherapy) in patients
without driver mutations. Both novel treatments have lesser toxicities
and better safety profile compared to chemotherapeutic agents.